Coronavirus prevention goes beyond vaccines.
News & Analysis: Merck & Co.
The U.S. government will pay $1.2 billion for 1.7 billion doses of Merck's experimental oral COVID-19 drug.
Older investors typically rely on income-producing investments to fund their golden years. These prospects offer a healthy balance of dividends, growth, and reliability.
They are all down after posting disappointing quarterly results -- but that just makes these fantastic income investments even better buys.
Which company should you consider buying right now?
Investors were not impressed with the company's latest quarterly update.
MRK earnings call for the period ending March 31, 2021.
The big drugmaker's declining vaccine sales were the biggest problem.
Its vaccine might not have panned out as expected, but Merck has more in the works.
Some healthcare companies are a good value even with the stock market at all-time highs.